<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830620</url>
  </required_header>
  <id_info>
    <org_study_id>12-PP-03</org_study_id>
    <nct_id>NCT02830620</nct_id>
  </id_info>
  <brief_title>Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy</brief_title>
  <acronym>CHIMIOKINES</acronym>
  <official_title>Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The syndrome of anorexia-cachexie, which accompanies numerous cancers is a major comorbidity&#xD;
      which compromises the forecast of these patients. Several cytokines pro-inflammatory as&#xD;
      interleukines IL1 ß, IL6 or TNFa participate in the physiopathology of this syndrome at the&#xD;
      man and the animal. Besides, it is now established that different neuronal populations,&#xD;
      localized in the hypothalamus, are nerve centers of the control of the appetite and the&#xD;
      energy homéostasie. However, there is not enough evidence of a direct action of cytokines on&#xD;
      these neurones, suggesting the participation of intermediate molecules as chimiokines,&#xD;
      inflammatory molecules produced in reaction to an immunological stress by gliales cells and&#xD;
      acting directly on the surrounding neurones. The implication of chimiokines in the syndrome&#xD;
      of anorexia-cachexie associated with the cancer thus seems very likely Among these,&#xD;
      chimiokines &quot; Monocyte Chemoattractant Proteins 1-3 &quot; or MCPs represent obvious candidates&#xD;
      because they are produced by multiple tumors. Furthermore, to the mouse, the intellectual&#xD;
      expression of MCP1 is correlated in the anorexia led by peripheral injections of a bacterial&#xD;
      by-product, the lipopolysaccharide (LPS).&#xD;
&#xD;
      The investigators' main objective is to test at the Man's, in situation of cancer of the&#xD;
      pancreas any confused stages, the degree of prédictivité of the chimiokine MCP1 towards the&#xD;
      syndrome of anorexia-cachexie associated with the cancer. The investigator also suggest&#xD;
      describing: i) the link between rate plasmatique of MCP1 and energy metabolism on one hand,&#xD;
      physical composition on the other hand;; ii) the impact of the other chimiokines,&#xD;
      particularly those of the family of the MCPs, on the anorexia-cachexie bound to the cancer,&#xD;
      iii) the correlation enters their profile of expression plasmatique and the severity of the&#xD;
      anorexia, the energy metabolism and the physical composition; iv) the same research on the&#xD;
      other inflammatory factors plasmatiques, of nature different from chimiokines; v) the&#xD;
      correlation between thin mass and anorexia; vi) the evolution of the chimiokines various and&#xD;
      inflammatory factors after surgical treatment or chemotherapy with curative aim in 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chimiokine MCP1 expression</measure>
    <time_frame>change from baseline to 180 days</time_frame>
    <description>Study at the Man's, in situation of cancer of the pancreas, diagnosed of novo and any confused stages, the prediction of the chimiokine MCP1 towards the syndrome of anorexia-cachexie associated with the cancer</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cancer of the Pancreas</condition>
  <condition>Anorexia</condition>
  <arm_group>
    <arm_group_label>groupe1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cancer of the pancreas WITH syndrome of anorexia-cachexie Dosage of chimiokines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>groupe2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cancer of the pancreas WITHOUT syndrome of anorexia-cachexie Dosage of chimiokines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>groupe3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>pure food limitation typifies restrictive anorexia nervosa Dosage of chimiokines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>groupe4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>unhurt individual of any appetite-suppressing evolutionary disease and cachectisante Dosage of chimiokines</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dosage of chimiokines</intervention_name>
    <arm_group_label>groupe1</arm_group_label>
    <arm_group_label>groupe2</arm_group_label>
    <arm_group_label>groupe3</arm_group_label>
    <arm_group_label>groupe4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1 {cancer of the pancreas WITH syndrome of anorexia-cachexie}&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient to hospitalize in the unit of digestive cancer research.&#xD;
&#xD;
          -  Patient ≥ 18 years.&#xD;
&#xD;
          -  Patient carrier of an adénocarcinome of the pancreas of novo, any stadium confused,&#xD;
             diagnosed by imaging and/or histology.&#xD;
&#xD;
          -  Existence of at least one of the criteria following to hold(retain) the diagnosis of&#xD;
             cachexie cancer patient: not deliberate loss of weight &gt; in 5 % over the last 6 months&#xD;
             OR(WHERE) IMC(CEREBRAL-MOTOR HANDICAPPED) &lt; 20 kg / m ² with a loss of minimum weight&#xD;
             &gt; 2 % OR(WHERE) scrawny muscular index appendiculaire respectively &lt; 7,26 kg / m ² at&#xD;
             the man and &lt; 5,45 kg / m ² at the woman with a minimal weight loss &gt; 2 %.&#xD;
&#xD;
          -  Patient having signed the enlightened consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having a tumor other one than the pancreatic adénocarcinome.&#xD;
&#xD;
          -  Patient having a second offense of adénocarcinome pancreatic.&#xD;
&#xD;
          -  Patient carrier of a pancreatic adénocarcinome in the course of a treatment by&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Patient having a severe psychiatric comorbidity except TCA who can be responsible for&#xD;
             food disorders.&#xD;
&#xD;
          -  Patient carrier of an evolutionary inflammatory disease other one than the cancer&#xD;
             being able to interfere on the inflammatory status.&#xD;
&#xD;
        Groupe 2 {cancer du pancréas SANS syndrome d'anorexie-cachexie}&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient to hospitalize in the(unit) of digestive cancer research.&#xD;
&#xD;
          -  Patient ≥ 18 years.&#xD;
&#xD;
          -  Patient carrier of an adénocarcinome of the pancreas of novo, any stadium confused,&#xD;
             diagnosed by imaging and/or histology.&#xD;
&#xD;
          -  Patient having signed a enlightened consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having a tumor other one than the pancreatic adénocarcinome.&#xD;
&#xD;
          -  Patient having a second offense(recurrence) of adénocarcinome pancreatic.&#xD;
&#xD;
          -  Patient carrier of a pancreatic adénocarcinome in the course of a treatment by&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Existence of at least one of the criteria in favour of the diagnosis of cachexie&#xD;
             cancer patient: not deliberate loss of weight &gt; in 5 % over the last 6 months&#xD;
             OR(WHERE) IMC(CEREBRAL-MOTOR HANDICAPPED) &lt; 20 kg / m ² with a loss of minimum weight&#xD;
             &gt; 2 % OR(WHERE) scrawny muscular index appendiculaire respectively &lt; 7,26 kg / m ² at&#xD;
             the man and &lt; 5,45 kg / m ² at the woman with a minimal weight loss &gt; 2 %.&#xD;
&#xD;
          -  Patient having a severe psychiatric comorbidity except TCA who can be responsible for&#xD;
             food disorders.&#xD;
&#xD;
          -  Patient carrier of an evolutionary inflammatory disease other one than the cancer&#xD;
             being able to interfere on the inflammatory status.&#xD;
&#xD;
          -  Patient refusing to participate in the study&#xD;
&#xD;
          -  Under guardianship patient or guardianship.&#xD;
&#xD;
        Group 3 {pure food limitation typifies restrictive anorexia nervosa}&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient seen in consultation in the unit of nutritional support(medium)&#xD;
&#xD;
          -  Patient ≥ 18 years.&#xD;
&#xD;
          -  Patient carrier of an eating disorder of type pure restrictive anorexia nervosa&#xD;
             (according to criterion diagnosis of the WHO)&#xD;
&#xD;
          -  Patient having signed a enlightened consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having any evolutionary organic pathology source of a decrease of the oral&#xD;
             contributions and/or the interference on the inflammatory status, and responsible for&#xD;
             a loss of weight&#xD;
&#xD;
          -  Patient refusing to participate in the study&#xD;
&#xD;
          -  Under guardianship patient or guardianship.&#xD;
&#xD;
        Group 4 {unhurt individual of any appetite-suppressing evolutionary disease and&#xD;
        cachectisante}&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient seen in consultation of hepatogastroenterology&#xD;
&#xD;
          -  Patient ≥ 18 years.&#xD;
&#xD;
          -  Unhurt patient of any organic or psychic, evolutionary pathology, cachectisante&#xD;
&#xD;
          -  Patient having signed a enlightened consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusing to participate in the study&#xD;
&#xD;
          -  Under guardianship patient or guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane SCHNEIDER, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane SCHNEIDER, Pr</last_name>
    <phone>04.92.03.59.23</phone>
    <email>schneider.s@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sthéphane SCHNEIDER, Pr</last_name>
      <phone>04.92.03.59.23</phone>
      <email>schneider.s@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane SCNEIDER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>July 8, 2016</last_update_submitted>
  <last_update_submitted_qc>July 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Anorexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

